Veru Inc. filings document regulatory disclosures for a Wisconsin biopharmaceutical company whose common stock trades on the Nasdaq Capital Market under VERU. Recent 8-K reports cover financial results, clinical program updates, material agreements, settlement of promissory-note obligations, security-holder rights, and capital-structure actions, including the completed 1-for-10 reverse stock split.
Proxy and annual-meeting records describe board elections, auditor ratification, executive compensation votes, and amendments to the 2018 Equity Incentive Plan. The filing record also includes Nasdaq listing-compliance disclosures and exhibits tied to Veru’s enobosarm and sabizabulin development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many VERU (VERU) SEC filings are available on StockTitan?
StockTitan tracks 41 SEC filings for VERU (VERU), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for VERU (VERU)?
The most recent SEC filing for VERU (VERU) was filed on July 25, 2025.